Analyzing R&D Budgets: Sarepta Therapeutics, Inc. vs Ionis Pharmaceuticals, Inc.

Biotech Giants' R&D Surge: A Decade of Growth

__timestamp	Ionis Pharmaceuticals, Inc.	Sarepta Therapeutics, Inc.
Wednesday, January 1, 2014	241751000	94231000
Thursday, January 1, 2015	322292000	146394000
Friday, January 1, 2016	344320000	188272000
Sunday, January 1, 2017	374644000	166707000
Monday, January 1, 2018	414604000	401843000
Tuesday, January 1, 2019	466000000	560909000
Wednesday, January 1, 2020	535000000	722343000
Friday, January 1, 2021	643000000	771182000
Saturday, January 1, 2022	833000000	877090000
Sunday, January 1, 2023	899625000	877387000

Cracking the code

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Ionis Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. have been at the forefront of this race.

From 2014 to 2023, Ionis Pharmaceuticals increased its R&D budget by nearly 273%, starting from approximately $242 million in 2014 to almost $900 million in 2023. Meanwhile, Sarepta Therapeutics demonstrated an even more aggressive growth, with its R&D expenses surging by over 830% from around $94 million in 2014 to nearly $877 million in 2023.

This trend underscores the escalating investment in groundbreaking therapies and the fierce competition in the biotech sector. As these companies continue to push the boundaries of medical science, their R&D investments are a testament to their dedication to advancing healthcare.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025